Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents.
Metoclopramide antagonises apomorphine-induced stereotypy in rats (ED50 1.5 mg/kg), apomorphine reversal of reserpine-induced locomotor suppression in mice (50% inhibition produced by 17 mg/kg), and apomorphine- or amphetamine-induced turning behaviour in mice with unilateral lesions of the striatal dopaminergic nerve terminals (ED505.0 and 4.0 mg/kg respectively). Metoclopramide resembles pimozide in all these respects and appears to be a relatively potent antagonist of striatal dopamine receptors. Yet metoclopramide, in anti-emetic doses, has no effect on disability in Parkinson's disease or on the therapeutic benefit of L-Dopa and L-Dopa dyskinesias.
D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors; D003342:Corpus Striatum / Q000502:physiology; D004298:Dopamine / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease; D010868:Pimozide / Q000494:pharmacology; D051381:Rats; D011955:Receptors, Drug; D012110:Reserpine / Q000037:antagonists & inhibitors; D012399:Rotation; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology
D011955:Receptors, Drug; D010868:Pimozide; D012110:Reserpine; D008787:Metoclopramide; D001058:Apomorphine; D004298:Dopamine